Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN

NCT07710534 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Relapsed / Refractory AML
High Risk Myelodysplastic Syndrome
High Risk Myeloproliferative Neoplasms

Interventions

DRUG: Decitabine-cedazuridine plus venetoclax (DEC-C+VEN)
DRUG: Azacitidine plus venetoclax (AZA+VEN)

Sponsor

Virginia Commonwealth University